Search

Displaying results 2331 - 2340 of 10000 in total
  1. Target

    NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6

    go.drugbank.com/bio_entities/BE0000376
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

    Synonyms: Complex I-B17
  2. Target

    NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial

    go.drugbank.com/bio_entities/BE0000676
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

    Synonyms: Complex I-ASHI
  3. Drug

    Bisphenol A diglycidyl ether

    go.drugbank.com/drugs/DB14083
    Approved

    Mixtures: Test Thin-Layer Rapid Use Patch Test
  4. Drug

    Dipentamethylenethiuram disulfide

    go.drugbank.com/drugs/DB14174
    Approved

    Mixtures: Test Thin-Layer Rapid Use Patch Test
  5. Drug

    N,N'-diphenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14192
    Approved

    Mixtures: Test Thin-Layer Rapid Use Patch Test
  6. Drug

    Raltegravir

    go.drugbank.com/drugs/DB06817
    ApprovedInvestigational

    Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

    Synonyms: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
  8. Drug

    Warfarin

    go.drugbank.com/drugs/DB00682
    ApprovedInvestigational

    Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. … Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use.

  9. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis.

  10. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI. … Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for _in vivo_ diagnostic imaging procedures